Abstract：【Objective】This study aims to explore the expression of Human Epidermal Growth Factor Receptor 2 (HER2) and Wilms' Tumor 1 (WT-1) in epithelial ovarian cancer (EOC) and their impact on patient prognosis.【Methods】 Clinical and pathological data of 86 patients diagnosed with primary EOC, who underwent surgical treatment at Shenmu City Hospital, were collected. The expression of HER2 and WT-1 in cancerous and adjacent non-cancerous tissues was analyzed, along with their relationship to clinical pathological characteristics and patient prognosis. 【Results】 The positive expression rates of HER2 and WT-1 in cancerous tissues were significantly higher than those in adjacent non-cancerous tissues (P<0.05). There were no statistically significant differences in the positive expression rates of HER2 and WT-1 across different ages, histological types, and lymph node metastasis status (P>0.05). However, differences in their expression rates were statistically significant when comparing FIGO stages and differentiation degrees (P<0.05). Kaplan-Meier survival analysis showed a statistically significant difference in survival rates between the two groups (P<0.05).【Conclusion】 There are significant differences in the positive expression rates of HER2 and WT-1 among EOC patients with different tumor stages and degrees of differentiation in both cancerous and adjacent non-cancerous tissues. Moreover, patients with positive expression of HER2 and WT-1 have a worse prognosis.
刘红霞, 张院院. HER2、WT-1在卵巢上皮性癌中的表达及对患者预后的影响[J]. 医学临床研究, 2025, 42(4): 645-648.
LIU Hongxia, ZHANG Yuanyuan. Expression of HER2 and WT-1 in Epithelial Ovarian Cancer and their Impact on Disease Prognosis. JOURNAL OF CLINICAL RESEARCH, 2025, 42(4): 645-648.
[1] 金福军. 卵巢上皮性癌腹腔转移机制及治疗的研究进展[J].重庆医学,2022,51(12):2140-2144. [2] CRASTA J, RAVIKUMAR G, RAJARAJAN S, et al. Expression of HER2 and EGFR proteins in advanced stage high-grade serous ovarian tumors show mutual exclusivity[J].Int J Gynecol Pathol,2021, 40(1):49-55. [3] 蒙秋,吴清萍,黄守国.WT-1基因在子宫颈癌组织细胞中的表达及意义[J].疑难病杂志,2013,12(8):614-616. [4] 《肿瘤病理诊断规范》项目组. 肿瘤病理诊断规范(卵巢癌及交界性上皮性肿瘤)[J].中华病理学杂志, 2018,47(5):324-327. [5] 马大烈, 白辰光. 免疫组织化学阳性标记结果的观察和判断[J].临床与实验病理学杂志, 2003, 19(5):557-559. [6] 顾思佳,杨佳妮,金悦,等.分子成像技术在卵巢上皮性癌中的研究进展及应用[J].实用妇产科杂志,2022,38(3):202-206. [7] 陈海琛,李旭苗,刘立媛,等.上皮性卵巢恶性肿瘤中PCNA、HER2、Vimentin及E-Cadherin表达与临床病理特征的关系[J].海南医学,2022,33(23):3085-3089. [8] ZHORDANIA K, GOKADZE N . 386 Diagnostic significance of p53, p16, wt1 in lavage samples from uterine cavity for serous ovarian cancer detection[J].BMJ Publishing Group Ltd,2020,30(3):161. [9] 史圆圆,徐国才,张丙忠.负液检查点HHLA2在上皮性卵巢癌中的表达及临床意义[J].现代妇产科进展,2019,28(6):438-441. [10] 孙志杰,申培红,杨琛擘,等. P53、PTEN和HER2蛋白在原发性卵巢上皮性癌组织中的表达及相关性分析[J].河南医学研究,2019,28(16):2881-2884. [11] 蔺楠,任超,蔡炯.HER2在卵巢上皮性癌中的研究进展[J].标记免疫分析与临床,2019,26(8):1418-1423. [12] ANTHONY R, NARAYANAN V . Expression of WT1 and PAX8 in the epithelial tumours of Malaysian women with ovarian cancer[J].British J Bio Sci,2017,19(3):65-70. [13] 李会,王俊杰. WT1和VEGF在卵巢上皮性癌组织中的表达及临床意义[J].中国老年学杂志,2017,37(22):5609-5610.
2025, Vol. 42 
